drugset / Trial / NCT00088205

Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma

NCT00088205

Phase 2 Completed 60 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purposes of this study are to determine the safety of oral enzastaurin and any side effects that might be associated with it and whether enzastaurin can help participants with mantle cell lymphoma.

Timeline

Start
2004-03
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 500 mg Oral

Indications